Approfondimenti generali
American Society of Clinical Oncology (ASCO) [Apri]
Neoplasie della mammella, Linee Guida AIOM, 2018 [Apri]
ESMO Clinical Practice Guidelines: Breast Cancer [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Murphy CG., Dickler MN. The Role of CDK 4/6 Inhibitions in Breast Cancer. The Oncologist 2015; 20:483–490 [Apri]
Witzel I., Müller V. The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment. Breast Care 2016;11:165–166 [Apri]
O’Sullivan CC. Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors. Int J Cancer Clin Res. 2015 ; 2(4) [Apri]
Sarah R, et al. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmacogenomics and Personalized Medicine 2014:7 203–215 [Apri]
Finn et al. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Research (2016) 18:17 [Apri]